News - Sitagliptin
Linagliptin (trade name: Trajenta®) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise.
Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease (CKD).
Regulators from the U.S. Food and Drug Administration have approved a new combination drug that will combine medicines used to treat diabetes and reduce cholesterol, various media outlets reported on Friday.
Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.govConsumer Inquiries: